Rovin Capital’s AbbVie ABBV Stock Holding History

Rovin Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$293K	Buy	1,282 +149	+13%	+$33.9K	0.08%	175
2025 Q3	$262K	Buy	+1,133	New	+$231K	0.07%	177
2025 Q2	–	Sell	-1,133	Closed	-$237K	–	188
2025 Q1	$237K	Buy	+1,133	New	+$220K	0.08%	169

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Rovin Capital's ABBV Position: Q4 2025 in Review

Rovin Capital increased its AbbVie (ABBV) stake by 13% in Q4 2025, buying an estimated $33.9K and bringing the position to 1,282 shares worth $293K. The position accounts for 0.08% of the portfolio, ranked #175.

Rovin Capital first reported a position in ABBV in Q1 2025 and has held it in 3 quarters since. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Rovin Capital held 1,282 shares of AbbVie worth $293K as of Q4 2025.
Rovin Capital bought 149 AbbVie shares in Q4 2025, an estimated $33.9K.
AbbVie made up 0.08% of Rovin Capital's portfolio in Q4 2025, its #175 holding.
Rovin Capital first reported a position in AbbVie in Q1 2025 and has held it in 3 quarters since.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Rovin Capital's 13F filing for Q4 2025, filed 9 Feb 2026.